	US 12,220,442 B2
	Antiepileptic toxin Martentoxin and use thereof
Chunyang Cao, Shanghai (CN); Yonghua Ji, Shanghai (CN); Xinlian Liu, Shanghai (CN); Jie Tao, Shanghai (CN); Shuzhang Zhang, Shanghai (CN); and Chunxi Wang, Shanghai (CN)
Assigned to Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai (CN)
Appl. No. 17/291,016
Filed by Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai (CN)
PCT Filed Nov. 5, 2019, PCT No. PCT/CN2019/115704 § 371(c)(1), (2) Date May 4, 2021, PCT Pub. No. WO2020/094002, PCT Pub. Date May 14, 2020.
Claims priority of application No. 201811307810.6 (CN), filed on Nov. 5, 2018.
Prior Publication US 2022/0040260 A1, Feb. 10, 2022
Int. Cl. A61K 38/17 (2006.01); A61K 38/00 (2006.01); A61K 45/06 (2006.01); A61P 25/08 (2006.01)

CPC A61K 38/1767 (2013.01) [A61K 45/06 (2013.01); A61P 25/08 (2018.01)]

14 Claims

1. A method of treating epilepsy in a subject in need thereof, comprising administering to the subject a composition comprising a MarTX toxin or a pharmaceutically acceptable salt thereof, wherein the MarTX toxin consists of the amino acid sequence of SEQ ID NO: 3.